• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Bausch + Lomb Corporation

    8/1/24 4:48:38 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    S-8 1 d745037ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 1, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Bausch + Lomb Corporation

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Canada   3851   98-1613662
    (State or Other Jurisdiction of
    Incorporation or Organization)
     

    (Primary Standard Industrial

    Classification Code Number)

      (I.R.S. Employer
    Identification No.)

    520 Applewood Crescent

    Vaughan, Ontario

    Canada, L4K 4B4

    (905) 695-7700

    (Address of Principal Executive Offices)

    Bausch + Lomb Corporation 2022 Omnibus Incentive Plan

    (Full Title of the Plan)

    A. Robert D. Bailey

    Executive Vice President & Chief Legal Officer

    Bausch + Lomb Corporation

    520 Applewood Crescent

    Vaughan, Ontario

    Canada, L4K 4B4

    (905) 695-7700

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, ” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐ (Do not check if a smaller reporting company)    Smaller reporting company   ☐
         Emerging Growth Company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Bausch + Lomb Corporation, a company incorporated under the Canada Business Corporations Act (the “Company” or “Registrant”) pursuant to and in accordance with the requirements of General Instruction E to Form S-8 for the purpose of registering an additional 14,000,000 Common Shares, no par value per share (“Common Shares”), of the Company that are issuable at any time or from time to time under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated effective as of May 29, 2024 (the “Plan”), and any additional Common Shares that become issuable under the Plan by reason of any stock dividend, stock split, or other similar transaction pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”).

    Pursuant to General Instruction E to Form S-8, the contents of the Registration Statement on Form S-8 filed for the Plan with the Securities and Exchange Commission (the “Commission”) on May 6, 2022 (Registration No. 333- 264728) and on August 2, 2023 (Registration No. 333-273621), including the documents incorporated by reference therein, are incorporated by reference into this Registration Statement, except as supplemented by the information set forth below.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act, and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the Plan, as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents are incorporated herein by reference:

    (a) The Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on February 21, 2024 (the “Annual Report”), including the sections of the Registrant’s Definitive Proxy Statement on Schedule 14A for the Registrant’s 2024 Annual Meeting of Stockholders, as filed with the Commission on April 29, 2024, incorporated by reference in the Annual Report;

    (b) The Company’s Quarterly Report on Form 10-Q for the quarter ended March  31, 2024, filed with the Commission on May 1, 2024, and for the quarter ended June 30, 2024, filed with the Commission on August 1, 2024;

    (c) The Company’s Current Reports on Form 8-K filed with the Commission on February 28, 2024 (except for the information furnished under Item 7.01) and May 29, 2024; and

    (d) The description of the Registrant’s share capital which is contained in the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (Registration No. 001-41380), filed with the Commission on August 2, 2023, including any amendments or supplements thereto.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to shareholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 8. Exhibits.

     

    Exhibit
    Number

        
      4.1    Amended Articles of Bausch + Lomb Corporation, originally filed as Exhibit 3.1 to Bausch + Lomb Corporation’s Form 8-K filed with the Commission on May 10, 2022.
      4.2    Amended By-laws of Bausch + Lomb Corporation, originally filed as Exhibit 3.2 to Bausch + Lomb Corporation’s Form 8-K filed with the Commission on May 10, 2022.
      5.1*    Opinion of Osler, Hoskin & Harcourt LLP
     23.1*    Consent of PricewaterhouseCoopers LLP
     23.2*    Consent of Osler, Hoskin & Harcourt LLP (included in Exhibit 5.1)
     24*    Powers of Attorney (included in signature pages hereof)
     99*    Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated effective as of May 29, 2024.
    107*    Filing Fee Table

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bridgewater, State of New Jersey, on August 1, 2024.

     

    BAUSCH + LOMB CORPORATION
    By:   /s/ A. Robert D. Bailey
      Name:   A. Robert D. Bailey
      Title:   Executive Vice President and Chief Legal Officer


    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brenton L. Saunders, Sam A. Eldessouky and A. Robert D. Bailey, and each or any one of them, as his or her true and lawful attorneys-in-fact and agents, upon the action of such appointee, with full power of substitution and resubstitution, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which each of said attorneys-in-fact and agents may deem necessary or advisable in order to enable the Registrant to comply with the Securities Act, and any requirements of the Commission in respect thereof, in connection with the filing with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto each of said attorneys-in-fact and agents full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact, or their substitutes, and agents may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:


    Signature

      

    Title

     

    Date

    /s/ Brenton L. Saunders

    Brenton L. Saunders

      

    Chief Executive Officer and Chairman

    (principal executive officer)

      August 1, 2024

    /s/ Sam A. Eldessouky

    Sam A. Eldessouky

      

    Chief Financial Officer

    (principal financial officer)

      August 1, 2024

    /s/ Frederick J. Munsch

    Frederick J. Munsch

      

    Chief Accounting Officer

    (principal accounting officer)

      August 1, 2024

    /s/ Thomas W. Ross, Sr.

    Thomas W. Ross, Sr.

       Lead Independent Director   August 1, 2024

    /s/ Nathalie Bernier

    Nathalie Bernier

       Director   August 1, 2024

    /s/ Gary Hu

    Gary Hu

       Director   August 1, 2024

    /s/ Brett Icahn

    Brett Icahn

       Director   August 1, 2024

    /s/ Sarah B. Kavanagh

    Sarah B. Kavanagh

       Director   August 1, 2024

    /s/ Karen L. Ling

    Karen L. Ling

       Director   August 1, 2024

    /s/ John A. Paulson

    John A. Paulson

       Director   August 1, 2024

    /s/ Russel C. Robertson

    Russel C. Robertson

       Director   August 1, 2024

    /s/ Andrew C. von Eschenbach

    Andrew C. von Eschenbach

       Director   August 1, 2024
    Get the next $BLCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    1/5/2026$18.00Outperform → In-line
    Evercore ISI
    12/11/2025$20.00Neutral → Buy
    Citigroup
    12/2/2025$21.00Equal-Weight → Overweight
    Morgan Stanley
    10/1/2025$16.00Neutral
    Goldman
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026   Time: 8:00 a.m. ET   Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392   Pa

    1/20/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

    Bausch + Lomb to launch fifth annual fundraising challenge during Glaucoma Awareness Month in partnership with Glaucoma Research Foundation, with all proceeds supporting glaucoma research Bausch + Lomb will also sponsor The Glaucoma Foundation's annual month-long educational social media campaign, which spotlights stories from glaucoma patients and advocates Glaucoma affects about four million people in the United States1 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundation (GRF) during Glaucoma Awareness Month in Ja

    1/5/26 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously announced credit agreement refinancing. In connection with the closing, Bausch + Lomb has entered into a fourth amendment (the "Fourth Amendment") to its existing credit agreement providing for a $2,802,125,000 tranche (the "Replacement Term Loans") of new term B loans, the proceeds of which were used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans") and its outstanding term B loans due 2028 (the "First Incremental Term Loans"). The am

    1/2/26 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bausch + Lomb downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00

    1/5/26 8:46:17 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Citigroup with a new price target

    Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00

    12/11/25 8:44:49 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00

    12/2/25 8:17:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/27/25 8:16:24 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/6/25 4:30:10 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/24 5:29:48 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BLCO
    SEC Filings

    View All

    SEC Form 3 filed by new insider Collis Steven H

    3 - Bausch & Lomb Corp (0001860742) (Issuer)

    1/9/26 6:39:51 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Alfonso Eduardo

    3 - Bausch & Lomb Corp (0001860742) (Issuer)

    1/9/26 6:06:45 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Robertson Russel C was granted 1,642 shares, increasing direct ownership by 3% to 66,556 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    11/18/25 4:42:57 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    1/2/26 4:10:34 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Amendment: Bausch + Lomb Corporation filed SEC Form 8-K: Leadership Update

    8-K/A - Bausch & Lomb Corp (0001860742) (Filer)

    12/22/25 4:10:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by Bausch + Lomb Corporation

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    12/17/25 4:44:26 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026   Time: 8:00 a.m. ET   Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392   Pa

    1/20/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Third-Quarter 2025 Results

    Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con

    10/29/25 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 29, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its product pipeline which features potential game-changing innovations in each business unit. T

    9/29/25 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care